KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to $116.7 million.

  • Evolent Health's Cash & Equivalents rose 2082.87% to $116.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.7 million, marking a year-over-year increase of 2082.87%. This contributed to the annual value of $104.2 million for FY2024, which is 4595.98% down from last year.
  • Per Evolent Health's latest filing, its Cash & Equivalents stood at $116.7 million for Q3 2025, which was up 2082.87% from $151.0 million recorded in Q2 2025.
  • In the past 5 years, Evolent Health's Cash & Equivalents ranged from a high of $266.3 million in Q4 2021 and a low of $96.6 million during Q3 2024
  • Moreover, its 5-year median value for Cash & Equivalents was $184.5 million (2023), whereas its average is $177.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 24739.2% in 2021, then crashed by 4766.17% in 2024.
  • Evolent Health's Cash & Equivalents (Quarter) stood at $266.3 million in 2021, then fell by 29.32% to $188.2 million in 2022, then increased by 2.46% to $192.8 million in 2023, then crashed by 45.96% to $104.2 million in 2024, then rose by 11.99% to $116.7 million in 2025.
  • Its Cash & Equivalents was $116.7 million in Q3 2025, compared to $151.0 million in Q2 2025 and $246.5 million in Q1 2025.